A Scoping Review of Medications Studied in Pediatric Polypharmacy Research

Alexis E. Horace, Negar Golchin, Elia M.Pestana Knight, Neal V. Dawson, Xuan Ma, James A. Feinstein, Hannah K. Johnson, Lawrence Kleinman, Paul M. Bakaki

Research output: Contribution to journalReview article

Abstract

Purpose: The purpose of this study is to describe medications most commonly studied in pediatric polypharmacy research by pharmacologic classes and disease using a scoping review methodology. Methods: A search of electronic databases was conducted in July 2019 that included Ovid Medline, PubMed, Elsevier Embase, and EBSCO CINAHL. Primary observational studies were selected if they evaluated polypharmacy as an aim, outcome, predictor, or covariate in children 0–21 years of age. Studies not differentiating between adults and children or those not written in English were excluded. Study characteristics, pharmacologic categories, medication classes, and medications were extracted from the included studies. Results: The search identified 8790 titles and after de-duplicating and full-text screening, 414 studies were extracted for the primary data. Regarding global pharmacologic categories, central nervous system (CNS) agents were most studied (n = 185, 44.9%). The most reported pharmacologic category was the anticonvulsants (n = 250, 60.4%), with valproic acid (n = 129), carbamazepine (n = 123), phenobarbital (n = 87), and phenytoin (n = 83) being the medications most commonly studied. In studies that reported medication classes (n = 105), serotonin reuptake inhibitors (n = 32, 30.5%), CNS stimulants (n = 30, 28.6%), and mood stabilizers (n = 27, 25.7%) were the most studied medication classes. Conclusion: While characterizing the literature on pediatric polypharmacy in terms of the types of medication studied, we further identified substantive gaps within this literature outside of epilepsy and psychiatric disorders. Medications frequently identified in use of polypharmacy for treatment of epilepsy and psychiatric disorders reveal opportunities for enhanced medication management in pediatric patients.

Original languageEnglish (US)
Pages (from-to)85-94
Number of pages10
JournalPediatric Drugs
Volume22
Issue number1
DOIs
StatePublished - Feb 1 2020

Fingerprint

Polypharmacy
Pediatrics
Research
Psychiatry
Epilepsy
Central Nervous System Agents
Central Nervous System Stimulants
Carbamazepine
Serotonin Uptake Inhibitors
Valproic Acid
Phenytoin
Phenobarbital
PubMed
Anticonvulsants
Observational Studies
Databases
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Pharmacology (medical)

Cite this

Horace, A. E., Golchin, N., Knight, E. M. P., Dawson, N. V., Ma, X., Feinstein, J. A., ... Bakaki, P. M. (2020). A Scoping Review of Medications Studied in Pediatric Polypharmacy Research. Pediatric Drugs, 22(1), 85-94. https://doi.org/10.1007/s40272-019-00372-4
Horace, Alexis E. ; Golchin, Negar ; Knight, Elia M.Pestana ; Dawson, Neal V. ; Ma, Xuan ; Feinstein, James A. ; Johnson, Hannah K. ; Kleinman, Lawrence ; Bakaki, Paul M. / A Scoping Review of Medications Studied in Pediatric Polypharmacy Research. In: Pediatric Drugs. 2020 ; Vol. 22, No. 1. pp. 85-94.
@article{a437843d139c4286a84d4178beee5039,
title = "A Scoping Review of Medications Studied in Pediatric Polypharmacy Research",
abstract = "Purpose: The purpose of this study is to describe medications most commonly studied in pediatric polypharmacy research by pharmacologic classes and disease using a scoping review methodology. Methods: A search of electronic databases was conducted in July 2019 that included Ovid Medline, PubMed, Elsevier Embase, and EBSCO CINAHL. Primary observational studies were selected if they evaluated polypharmacy as an aim, outcome, predictor, or covariate in children 0–21 years of age. Studies not differentiating between adults and children or those not written in English were excluded. Study characteristics, pharmacologic categories, medication classes, and medications were extracted from the included studies. Results: The search identified 8790 titles and after de-duplicating and full-text screening, 414 studies were extracted for the primary data. Regarding global pharmacologic categories, central nervous system (CNS) agents were most studied (n = 185, 44.9{\%}). The most reported pharmacologic category was the anticonvulsants (n = 250, 60.4{\%}), with valproic acid (n = 129), carbamazepine (n = 123), phenobarbital (n = 87), and phenytoin (n = 83) being the medications most commonly studied. In studies that reported medication classes (n = 105), serotonin reuptake inhibitors (n = 32, 30.5{\%}), CNS stimulants (n = 30, 28.6{\%}), and mood stabilizers (n = 27, 25.7{\%}) were the most studied medication classes. Conclusion: While characterizing the literature on pediatric polypharmacy in terms of the types of medication studied, we further identified substantive gaps within this literature outside of epilepsy and psychiatric disorders. Medications frequently identified in use of polypharmacy for treatment of epilepsy and psychiatric disorders reveal opportunities for enhanced medication management in pediatric patients.",
author = "Horace, {Alexis E.} and Negar Golchin and Knight, {Elia M.Pestana} and Dawson, {Neal V.} and Xuan Ma and Feinstein, {James A.} and Johnson, {Hannah K.} and Lawrence Kleinman and Bakaki, {Paul M.}",
year = "2020",
month = "2",
day = "1",
doi = "10.1007/s40272-019-00372-4",
language = "English (US)",
volume = "22",
pages = "85--94",
journal = "Paediatric Drugs",
issn = "1174-5878",
publisher = "Adis International Ltd",
number = "1",

}

Horace, AE, Golchin, N, Knight, EMP, Dawson, NV, Ma, X, Feinstein, JA, Johnson, HK, Kleinman, L & Bakaki, PM 2020, 'A Scoping Review of Medications Studied in Pediatric Polypharmacy Research', Pediatric Drugs, vol. 22, no. 1, pp. 85-94. https://doi.org/10.1007/s40272-019-00372-4

A Scoping Review of Medications Studied in Pediatric Polypharmacy Research. / Horace, Alexis E.; Golchin, Negar; Knight, Elia M.Pestana; Dawson, Neal V.; Ma, Xuan; Feinstein, James A.; Johnson, Hannah K.; Kleinman, Lawrence; Bakaki, Paul M.

In: Pediatric Drugs, Vol. 22, No. 1, 01.02.2020, p. 85-94.

Research output: Contribution to journalReview article

TY - JOUR

T1 - A Scoping Review of Medications Studied in Pediatric Polypharmacy Research

AU - Horace, Alexis E.

AU - Golchin, Negar

AU - Knight, Elia M.Pestana

AU - Dawson, Neal V.

AU - Ma, Xuan

AU - Feinstein, James A.

AU - Johnson, Hannah K.

AU - Kleinman, Lawrence

AU - Bakaki, Paul M.

PY - 2020/2/1

Y1 - 2020/2/1

N2 - Purpose: The purpose of this study is to describe medications most commonly studied in pediatric polypharmacy research by pharmacologic classes and disease using a scoping review methodology. Methods: A search of electronic databases was conducted in July 2019 that included Ovid Medline, PubMed, Elsevier Embase, and EBSCO CINAHL. Primary observational studies were selected if they evaluated polypharmacy as an aim, outcome, predictor, or covariate in children 0–21 years of age. Studies not differentiating between adults and children or those not written in English were excluded. Study characteristics, pharmacologic categories, medication classes, and medications were extracted from the included studies. Results: The search identified 8790 titles and after de-duplicating and full-text screening, 414 studies were extracted for the primary data. Regarding global pharmacologic categories, central nervous system (CNS) agents were most studied (n = 185, 44.9%). The most reported pharmacologic category was the anticonvulsants (n = 250, 60.4%), with valproic acid (n = 129), carbamazepine (n = 123), phenobarbital (n = 87), and phenytoin (n = 83) being the medications most commonly studied. In studies that reported medication classes (n = 105), serotonin reuptake inhibitors (n = 32, 30.5%), CNS stimulants (n = 30, 28.6%), and mood stabilizers (n = 27, 25.7%) were the most studied medication classes. Conclusion: While characterizing the literature on pediatric polypharmacy in terms of the types of medication studied, we further identified substantive gaps within this literature outside of epilepsy and psychiatric disorders. Medications frequently identified in use of polypharmacy for treatment of epilepsy and psychiatric disorders reveal opportunities for enhanced medication management in pediatric patients.

AB - Purpose: The purpose of this study is to describe medications most commonly studied in pediatric polypharmacy research by pharmacologic classes and disease using a scoping review methodology. Methods: A search of electronic databases was conducted in July 2019 that included Ovid Medline, PubMed, Elsevier Embase, and EBSCO CINAHL. Primary observational studies were selected if they evaluated polypharmacy as an aim, outcome, predictor, or covariate in children 0–21 years of age. Studies not differentiating between adults and children or those not written in English were excluded. Study characteristics, pharmacologic categories, medication classes, and medications were extracted from the included studies. Results: The search identified 8790 titles and after de-duplicating and full-text screening, 414 studies were extracted for the primary data. Regarding global pharmacologic categories, central nervous system (CNS) agents were most studied (n = 185, 44.9%). The most reported pharmacologic category was the anticonvulsants (n = 250, 60.4%), with valproic acid (n = 129), carbamazepine (n = 123), phenobarbital (n = 87), and phenytoin (n = 83) being the medications most commonly studied. In studies that reported medication classes (n = 105), serotonin reuptake inhibitors (n = 32, 30.5%), CNS stimulants (n = 30, 28.6%), and mood stabilizers (n = 27, 25.7%) were the most studied medication classes. Conclusion: While characterizing the literature on pediatric polypharmacy in terms of the types of medication studied, we further identified substantive gaps within this literature outside of epilepsy and psychiatric disorders. Medications frequently identified in use of polypharmacy for treatment of epilepsy and psychiatric disorders reveal opportunities for enhanced medication management in pediatric patients.

UR - http://www.scopus.com/inward/record.url?scp=85076835413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076835413&partnerID=8YFLogxK

U2 - 10.1007/s40272-019-00372-4

DO - 10.1007/s40272-019-00372-4

M3 - Review article

C2 - 31823339

AN - SCOPUS:85076835413

VL - 22

SP - 85

EP - 94

JO - Paediatric Drugs

JF - Paediatric Drugs

SN - 1174-5878

IS - 1

ER -

Horace AE, Golchin N, Knight EMP, Dawson NV, Ma X, Feinstein JA et al. A Scoping Review of Medications Studied in Pediatric Polypharmacy Research. Pediatric Drugs. 2020 Feb 1;22(1):85-94. https://doi.org/10.1007/s40272-019-00372-4